Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases. Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins. The effects of AIM pharmacology have been documented in more than 200 scientific papers and are potentially relevant to a wide range of diseases.

Irving, US
Size (employees)
64 (est)
Reata Pharmaceuticals was founded in 2002 and is headquartered in Irving, US

Key People at Reata Pharmaceuticals

Warren Huff

Warren Huff

President and CEO

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has an office in Irving
Irving, US (HQ)
150 2801 Gateway Dr

Reata Pharmaceuticals Data and Metrics

Reata Pharmaceuticals Financial Metrics

Reata Pharmaceuticals's revenue was reported to be $49.9 m in FY, 2016 which is a 1% decrease from the previous period.
$, USD

Revenue (FY, 2016)

49.9 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(6.2 m)

Market capitalization (23-Jun-2017)

647.9 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

84.7 m
Reata Pharmaceuticals's current market capitalization is $647.9 m.
$, USDFY, 2015FY, 2016


50.3 m49.9 m

Revenue growth, %


R&D expense

35.1 m39.5 m

General and administrative expense

13.7 m16.6 m

Operating expense total

50.7 m56.7 m

Pre tax profit

(302 k)(6.7 m)

Income tax expense

1.1 m(441 k)

Net Income

(1.5 m)(6.2 m)
$, USDFY, 2015FY, 2016


42 m84.7 m


2.6 m

Current Assets

77.3 m87.3 m


1.1 m819 k

Total Assets

80 m89.1 m

Accounts Payable

3.8 m

Current Liabilities

60.8 m59.6 m

Non-Current Liabilities

291.3 m244.5 m

Total Liabilities

352.1 m304.1 m

Additional Paid-in Capital

10 m74.3 m

Retained Earnings

(283.1 m)(289.4 m)

Total Equity

(273.2 m)(215 m)

Financial Leverage

-0.3 x-0.4 x
$, USDFY, 2015FY, 2016

Net Income

(1.5 m)(6.2 m)

Depreciation and Amortization

1.8 m682 k


(1.2 m)

Accounts Payable

299 k

Cash From Operating Activities

(44.6 m)(19.3 m)

Purchases of PP&E

(272 k)(340 k)

Cash From Investing Activities

(260 k)(339 k)

Cash From Financing Activities

(870 k)62.3 m
$, USDY, 2016


779 k

Financial Leverage

-0.4 x

Reata Pharmaceuticals Operating Metrics

FY, 2016

Phase III Trials


Phase II Trials


Phase I Trials


Patents Granted


Patents Pending


Reata Pharmaceuticals Market Value History

Reata Pharmaceuticals Online and Social Media Presence

Reata Pharmaceuticals Company Life and Culture

You may also be interested in